Inflammatory demyelinating neuropathies.

Area of Science:

• Neurology
• Immunology

Background:

• Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are autoimmune neuropathies impacting nerve function.
• Therapeutic goals include enhancing muscle strength, functional ability, and alleviating pain and sensory deficits.

Purpose of the Study:

• To outline current therapeutic strategies for GBS and CIDP.
• To compare the efficacy and indications for different treatment modalities.

Main Methods:

• Review of standard and alternative treatments for GBS and CIDP.
• Discussion of factors influencing treatment selection, including disease severity, patient factors, and drug profiles.

Main Results:

• For GBS, plasma exchange (PE) and human immune globulin (HIG) demonstrate similar efficacy; PE is often preferred, with HIG used in specific pediatric cases or contraindications.
• For CIDP, corticosteroids, HIG, and PE are all effective; corticosteroids are frequently favored due to safety, cost, and administration ease.
• Treatment choice for CIDP depends on disease severity, patient comorbidities, and drug-specific considerations.

Conclusions:

• Treatment decisions for GBS and CIDP should be individualized based on patient characteristics and treatment efficacy.
• Corticosteroids are a preferred initial therapy for moderate to severe CIDP, with HIG as an alternative.
• PE is generally reserved for GBS or as a later-line treatment for CIDP.